Sjögren's Syndrome in Pregnancy: Risks and Management
Women with Sjögren's syndrome face increased pregnancy risks including preeclampsia, preterm delivery, intrauterine growth restriction, and most critically, congenital heart block in anti-Ro/SSA or anti-La/SSB positive mothers—requiring structured preconception counseling, hydroxychloroquine therapy, and intensive fetal cardiac surveillance.
Maternal and Fetal Risks
Maternal Complications
Women with Sjögren's syndrome experience significantly elevated risks compared to the general population 1:
- Preeclampsia: 1.63-fold increased risk
- Preterm delivery: 1.56-fold increased risk
- Cesarean delivery: 1.29-fold increased risk
- Premature rupture of membranes: 1.28-fold increased risk
- Venous thromboembolism: 3.71-fold increased risk
However, recent prospective data from the GR2 study provides reassurance that overall adverse pregnancy outcomes in Sjögren's syndrome (9%) are not significantly different from the general population (7%) when properly managed 2.
Fetal and Neonatal Risks
The most concerning fetal complications include 1, 3:
- Intrauterine growth restriction (IUGR): 3.0-fold increased risk
- Congenital malformations: 3.26-fold increased risk
- Congenital heart block (CHB): 0.7-2% risk in anti-Ro/SSA positive mothers, rising to higher rates with prior affected pregnancies
- Small-for-gestational-age: Increased incidence
- Neonatal lupus: Associated with anti-Ro/SSA and anti-La/SSB antibodies
Critical Risk Factors for Adverse Outcomes
Multivariate analysis identifies specific predictors requiring heightened surveillance 4, 2:
- Antiphospholipid antibody positivity: 50% of adverse outcomes occurred in aPL-positive pregnancies versus 4% in aPL-negative
- Anti-U1-RNP antibody positivity: 3.56-fold increased risk of adverse outcomes
- Subchorionic hemorrhage: 7.65-fold increased risk
- Advanced maternal age: Independent predictor (OR 1.40 per year)
Preconception Counseling and Risk Stratification
Essential Laboratory Testing
Test once before or early in pregnancy 5, 6:
- Anti-Ro/SSA antibodies
- Anti-La/SSB antibodies
- Lupus anticoagulant (LAC)
- Anticardiolipin antibodies (aCL) IgG/IgM
- Anti-β2-glycoprotein I (aβ2GPI) IgG/IgM
Do not repeat these tests during pregnancy as they remain stable 5.
Timing of Conception
Strongly recommend delaying pregnancy until disease is quiescent or in low activity state 5. Active disease at conception increases risks of:
- Disease flares during pregnancy (RR 2.1)
- Hypertensive complications (OR 1.8)
- Fetal loss and preterm delivery (OR 5.7 and 6.5 respectively) 6
Management During Pregnancy
Hydroxychloroquine: The Cornerstone of Therapy
All women with Sjögren's syndrome should take hydroxychloroquine during pregnancy 5, 6:
- If already on HCQ: Strongly recommend continuing (Grade 1/B evidence)
- If not on HCQ: Conditionally recommend starting if no contraindication (Grade 2/B evidence)
- Dosing: 400 mg daily 7
- Benefits: Reduces SLE flares, improves obstetrical outcomes, and may reduce anti-Ro/SSA antibody-mediated cardiac injury 6, 3
Low-Dose Aspirin
Start low-dose aspirin (81-100 mg daily) in women at risk for preeclampsia 5, 6:
- Those with lupus nephritis
- Those with positive antiphospholipid antibodies
- Initiate preconceptionally or no later than 16 weeks gestation 6
Antiphospholipid Antibody-Positive Patients
For women with positive aPL 5, 6:
- Obstetric APS: Low-dose aspirin + prophylactic heparin (Grade 1/A evidence)
- Thrombotic APS: Low-dose aspirin + therapeutic heparin
- Use LMWH over unfractionated heparin for practical reasons despite RCT evidence only for unfractionated heparin 6
Corticosteroids
Use prednisone only for acute, widespread disease flares 6:
- Conditional recommendation (Grade 3/C)
- Avoid routine prophylactic use due to maternal risks (infection, hypertension, weight gain, osteonecrosis) and fetal risks (IUGR, oligohydramnios, adrenal suppression) without demonstrated benefit 3
- Exception: Short-course dexamethasone may be considered for first- or second-degree heart block detected on fetal echo 5, 7
Medications to Avoid
Absolutely contraindicated 6:
- Mycophenolic acid
- Cyclophosphamide
- Leflunomide
- Methotrexate
Fetal Surveillance Protocol
For Anti-Ro/SSA or Anti-La/SSB Positive Mothers
Implement intensive fetal cardiac monitoring 5, 6:
Serial fetal echocardiography from 16-26 weeks gestation
If abnormal findings detected:
Supplementary surveillance:
- Doppler ultrasonography in third trimester
- Biometric parameters to screen for placental insufficiency and small-for-gestational-age fetuses 6
Cost-Effectiveness Caveat
The cost-effectiveness of intensive weekly/biweekly fetal echo surveillance in anti-Ro/La-positive women without prior CHB remains uncertain given the low 0.7-2% baseline risk 6. However, given the severity of complete CHB and lack of effective treatment once established, surveillance is still recommended.
Multidisciplinary Care Requirements
- Maternal-fetal medicine specialist
- Rheumatologist
- Pediatric cardiologist (for fetal echo interpretation)
- Neonatologist (for delivery planning)
Neonatal Considerations
For infants with in-utero exposure to maternal anti-Ro/SSA antibodies 5:
- Consult pediatrician regarding timing of live vaccines
- Monitor for neonatal lupus manifestations
- ECG and echocardiography at birth if maternal antibodies present
Postpartum Management
- Continue hydroxychloroquine
- Consider low-dose corticosteroids (e.g., methylprednisolone 6 mg daily) for disease suppression 7
- Thromboprophylaxis with LMWH for 4-6 weeks if aPL-positive
- Monitor for disease flares (13% flare rate in prospective cohort) 2
Key Clinical Pitfalls
- Failing to test for anti-Ro/SSA and aPL antibodies preconceptionally: These determine surveillance intensity and treatment strategy
- Discontinuing hydroxychloroquine due to pregnancy concerns: HCQ is safe and beneficial—stopping increases flare risk
- Delaying aspirin initiation beyond 16 weeks: Reduces effectiveness for preeclampsia prevention
- Using prophylactic steroids routinely: No proven benefit and significant maternal-fetal risks
- Inadequate fetal cardiac surveillance in anti-Ro/SSA-positive mothers: Complete heart block requires early detection for any intervention attempt
Bottom line: Sjögren's syndrome pregnancies require proactive risk stratification, continuation of hydroxychloroquine, structured fetal cardiac surveillance for antibody-positive mothers, and multidisciplinary coordination—but with proper management, most women achieve successful pregnancy outcomes comparable to the general population.